Navigation Links
Hepatitis C virus may need enzyme's help to cause liver disease
Date:7/9/2008

patitis C virus linked to an increase in fatty acids, Dr. Wang worked with Thomas Conrads, Ph.D., co-director of clinical proteomics at the University of Pittsburgh Cancer Institute, and colleagues on a mass spectrometry-based proteomics approach in which they measured protein expression from liver cell cultures exposed to the hepatitis C virus. The approach sorted proteins based on their weight and electrical charge, looking for divergent patterns linked to the virus. Of the 175 proteins they identified, only FAS was highly elevated in cell cultures. Furthermore, when they blocked the expression of FAS, they noted a three to four times decrease in the level of the virus, indicating that FAS is directly linked to the virus's expression.

"Viruses are very complex, so it is challenging to determine what proteins may be at play in their survival and growth," said Dr. Wang. "The proteomic approach we used revealed many proteins linked to hepatitis C that may be worthy of further study, but FAS appears to be the protein most strongly associated with the production of fatty acids that can cause liver disease."

"Our next step in this research is to see how high the level of FAS is in tissue samples from hepatitis C patients and determine whether elevated FAS levels directly result in overproduction of fat in livers. If we learn that FAS is highly present in tissue, testing for it may be a way to predict those at risk for liver disease."


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Who will recover spontaneously from hepatitis C virus infection
3. Possible hepatitis C vaccine
4. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
5. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
6. New hope for hepatitis C sufferers
7. BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
8. Features of replication suggest viruses have common themes, vulnerabilities
9. First all-African GM crop is resistant to maize streak virus
10. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
11. Gamma globulin effective in treating eye infections caused by adenoviruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Although the soluble factor TGF-beta has been shown to suppress ... breast cancer, high levels of TGF-beta during the later stages ... study using human breast cancer samples and mice, which appears ... January print issue of the Journal of Clinical Investigation, indicates ...
... successfully tested two candidate vaccines that may eventually be ... Their findings are published in the December 15 issue ... , Barney S. Graham, MD, PhD, and colleagues from ... in Maryland, the Fred Hutchinson Cancer Research Center in ...
... the University of Rochester may have answered one of ... neurons, which are responsible for our crystal-clear thoughts, seem ... November issue of Nature Neuroscience, the Rochester study shows ... signals to represent the ambiguities of the real world--and ...
Cached Biology News:Progress made in HIV vaccine development 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Calif., Jan. 22 Abaxis, Inc.,(Nasdaq: ABAX ), ... scheduled a conference call to discuss its,financial results for ... 2007. The call will be at 4:15 p.m. ET, ... 356-5706 or (706) 643-0580 to access the,conference call, or ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
... Marker Precision and ... Simultaneous Diagnostic Monitoring MUKILTEO, Wash. ... CBMX ) and Clarient, Inc. (Nasdaq: CLRT ),today ... a novel genomics-based cancer test called HemeScan(TM), a,comprehensive test related ...
Cached Biology Technology:Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6
Mouse BLC/BCA 1 - 10kDa...
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: